Some Supplements Can Make Your Medication Less Effective

Some vitamin and mineral supplements can interfere with absorption of medications (Oklahoma State University) 
Some vitamin and mineral supplements can interfere with absorption of medications (Oklahoma State University) 
TT

Some Supplements Can Make Your Medication Less Effective

Some vitamin and mineral supplements can interfere with absorption of medications (Oklahoma State University) 
Some vitamin and mineral supplements can interfere with absorption of medications (Oklahoma State University) 

Health experts warned that some supplements can interact with certain medications and reduce their effectiveness, according to Eating Well website.

While these supplements are usually sold over-the-counter, taking them without asking a health care provider can have dangerous impact on your health.

Naturopathic doctor Jacob Wolf said that for instance, some vitamin and mineral supplements can interfere with absorption of medications.

Other supplements can bind with medications, preventing the drug from being utilized in the body, or they may be metabolized by the same or similar pathways as medications, explains Wolf. That can have a dangerous impact on your health.

Top offenders include calcium, magnesium, iron, fiber, activated charcoal and vitamins C and K.

Minerals like calcium, magnesium and iron can bind with medications, especially levothyroxine, a drug used to treat hypothyroidism, said Wolf.

“This can impact how levothyroxine is utilized in the body, adversely affecting treatment,” he explained.

These minerals can also interact with antibiotics in the tetracycline and fluoroquinolone class, said pharmacist Amanda Corbett.

Taking these mineral supplements at the same time as antibiotics may reduce the bioavailability of the antibiotic, creating risks like bacterial resistance or ineffective treatment.

And while scientists affirm fiber is an important nutrient for digestive regularity, healthy cholesterol levels and blood sugar management, supplementing isn’t always a great idea, as large doses can impact the absorption of certain medications.

Fiber-rich foods are a cornerstone of blood sugar management, even for those taking blood sugar–lowering medications, like metformin.

Fiber may also impair the effectiveness of other drugs, including digoxin (which treats certain heart conditions) and levothyroxine for hypothyroidism, Wolf said.

Therefore, if you do choose to take a fiber supplement, Wolf recommended speaking with your health care provider about spacing out your fiber and medication doses.

As for activated charcoal, it is a form of carbon that is used in the emergency room to treat the ingestion of toxic drugs and poisons.

“Activated charcoal acts like a sponge and can bind to many medications. It is best to completely avoid activated charcoal if on any life-critical medication,” said Wolf.

For Vitamin C, it is an important antioxidant that protects cells from free radical damage and supports proper immune system function.

However, if you are undergoing chemotherapy treatment for cancer, experts strongly caution against taking vitamin C supplements.

“Vitamin C can lead to certain chemotherapies being less effective or ineffective in treating cancer,” said Corbett.

Vitamin E, another antioxidant, can also interfere with chemotherapy’s effectiveness.

If taking Vitamin K, which is a fat-soluble vitamin that helps blood clot and shores up bone health, you should know that it can reduce the effectiveness of a blood-thinning medication called warfarin (Coumadin).

That, in turn, can make blood more likely to clot, which can lead to a heart attack or stroke.

If you are taking warfarin, you don’t necessarily need to avoid vitamin K, but it is critical to keep the amount you consume—from both foods and supplements—consistent to avoid clotting problems.

Experts advise that to take supplements safely, consult with your health care provider.

Many supplements can interact with medications, and so it’s critical to connect with your prescribing health care provider to make sure that the supplements you’re taking play nice with your medications.

Also, look for those that have been independently tested in a laboratory, recommended Corbett.

Experts say you should also know how much to take. Supplement dosages are listed on the label, but they aren’t standardized.

That means they can vary from product to product, and may far exceed safe levels.

 

 

 



Trump's Triumphal Arch Gets Official Name

White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP
White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP
TT

Trump's Triumphal Arch Gets Official Name

White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP
White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP

It's been dubbed the "Arc de Trump." But now President Donald Trump's latest building project has an official name -- the "United States Triumphal Arch."

White House Press Secretary Karoline Leavitt revealed the formal title on Wednesday, saying the giant structure was being built to mark the 250th anniversary of US independence, AFP reported.

"In honor of this historic occasion, President Trump and the Department of Interior will submit plans for the United States Triumphal Arch," Leavitt told reporters.

Showing off a picture that she initially held upside down, Leavitt said the "monumental" arch would stand 250 feet (76.2 meters) tall "in honor of 250 years."

Its colossal height, including a huge golden Lady Liberty statue on top, means it will dwarf perhaps its most famous predecessor, the Arc de Triomphe in Paris, which stands at 164 feet.

In fact it is set to be the largest structure of its kind in the world, pipping Mexico City's Monument to the Revolution and knocking Pyongyang's Arch of Triumph to third place.

Plans for the arch were first revealed in October when AFP journalists spotted a model on Trump's desk in the Oval Office, after which it was quickly dubbed the "Arc de Trump" by US media.

Trump revealed the first full renderings for the structure last Friday.

The arch is one of several architectural projects -- including the construction of a gigantic White House ballroom and renovations to the Kennedy Center for the Performing Arts -- that Trump has undertaken to leave a mark on Washington in his second term.

Critics say the gold-accented arch, which will tower over the 99-foot-tall Lincoln Memorial, is a monument to the 79-year-old Trump's vanity.

The arch will partly be funded by US taxpayers, getting $2 million in special funds from the US National Endowment for the Humanities, with up to $13 million in funds to match any donations, ABC News reported.

But Leavitt said it was aimed at celebrating US national pride.

"Long after everyone in this room is gone, our children and grandchildren will remain inspired by this national monument," she told reporters.


Much-hyped Alzheimer's Drugs Do Not Help Patients, Review Finds

New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File
New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File
TT

Much-hyped Alzheimer's Drugs Do Not Help Patients, Review Finds

New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File
New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File

Drugs once hailed as a breakthrough in the fight against Alzheimer's disease do not meaningfully help patients, a major review found Thursday, however some experts criticized the research.

The review by the Cochrane organization -- which is considered the gold standard for analyzing existing evidence -- looked at drugs that target a plaque called amyloids which builds up in the brains of Alzheimer's patients.

Researchers have long sought a way to eliminate this plaque, believing it could be the cause of the most common form of dementia which affects millions of elderly people every year, said AFP.

After decades of costly yet unsuccessful research, two anti-amyloid drugs called lecanemab and donanemab were initially hailed as gamechangers that finally offered a way to slow the progress of the debilitating disease.

Both drugs were approved by the United States and European Union over the last few years.

However concerns about their effectiveness, cost and side effects including an increased risk of brain swelling and bleeding have since prompted caution. State-run health services in the UK and France have refused to cover the drugs.

The new Cochrane review combined data from 17 clinical trials that included a total of more than 20,000 people with mild cognitive impairment or early dementia.

The trials, which took place over roughly 18 months, studied seven different anti-amyloid drugs.

Only one of the trials examined donanemab -- sold under the name Kisunla by US pharma giant Eli Lilly -- while one studied lecanemab, sold as Leqembi by Biogen and Eisai.

While early trials suggested these drugs made a statistically significant difference, this did not translate into "something clinically meaningful for patients," lead study author Francesco Nonino of Italy's IRCCS institute told a press conference.

Brain scans showed that the drugs successfully removed amyloids, the researchers emphasized.

This means "the idea that removing amyloids will benefit patients was refuted by our results," said study co-author Edo Richard of Radboud University Medical Center in the Netherlands.

- 'Not delivering on promise' -

Richard, who has previously expressed skepticism about anti-amyloid drugs, said he hopes efforts targeting other mechanisms that potentially cause Alzheimer's lead to more effective drugs in the future.

British biologist John Hardy, who first developed the amyloid hypothesis in the 1990s, criticized the review for lumping together data about lecanemab and donanemab along with drugs that are known to be ineffective, therefore dragging down the overall average.

"This is a silly paper which should not have been published," Hardy told AFP, disclosing that he has consulted for Eli Lilly, Biogen and Eisai.

In response to such questions, Richard said that while the drugs included in the study may work in different ways, they all have the same target: amyloid beta proteins.

Australian neuroscientist Bryce Vissel, who was not involved in the research, said it "does not prove amyloid has no role in Alzheimer's, and it does not rule out future amyloid-directed therapies that may yet help patients".

"But it does show that the current generation of anti-amyloid drugs is not delivering the promise that has surrounded it."


Indonesia Police Arrest Six for Komodo Dragon Smuggling

A komodo dragon is displayed by nature and conservation agency officials and police officers after being seized from suspects attempting to smuggle it into Thailand, during a press conference at the regional police headquarters in Surabaya on April 15, 2026. (Photo by JUNI KRISWANTO / AFP)
A komodo dragon is displayed by nature and conservation agency officials and police officers after being seized from suspects attempting to smuggle it into Thailand, during a press conference at the regional police headquarters in Surabaya on April 15, 2026. (Photo by JUNI KRISWANTO / AFP)
TT

Indonesia Police Arrest Six for Komodo Dragon Smuggling

A komodo dragon is displayed by nature and conservation agency officials and police officers after being seized from suspects attempting to smuggle it into Thailand, during a press conference at the regional police headquarters in Surabaya on April 15, 2026. (Photo by JUNI KRISWANTO / AFP)
A komodo dragon is displayed by nature and conservation agency officials and police officers after being seized from suspects attempting to smuggle it into Thailand, during a press conference at the regional police headquarters in Surabaya on April 15, 2026. (Photo by JUNI KRISWANTO / AFP)

Indonesian authorities said Wednesday they have arrested six people allegedly involved in smuggling endangered Komodo dragons native to the archipelago and destined for Thailand.

Two suspects were arrested in February in the port city of Surabaya on the east coast of Java island as they got off a ship with three live Komodo dragons -- the world's largest living lizard.

Further investigation led to four more arrests in the weeks that followed, AFP reported.

Police said the animals had been obtained from "suppliers or hunters" in Indonesia's East Nusa Tenggara province, where they are native to a handful of small islands.

The suspects are accused of buying the dragons for 5.5 million rupiah (about $320) apiece and selling them for six times the price, apparently to be shipped to clients in Thailand.

According to East Java police, the suspects have smuggled and traded at least 20 Komodo dragons since January last year, and pocketed some $33,000.

They face up to five years in prison and a fine.

The International Union for Conservation of Nature lists the Komodo dragon as endangered, with a global population of about 3,400, including juveniles.

The fearsome reptiles, which can grow to three meters (10 feet) in length and weigh up to 90 kilograms (200 pounds), are threatened by human activity and by climate change destroying their habitat.

Poachers collect them to be sold as pets or display animals.

Komodo dragons in the wild are found only in Indonesia's World Heritage-listed Komodo National Park and on neighboring Flores island.

Police said Wednesday they had also arrested two suspects for smuggling 140 kilograms of pangolin scales from the northwestern province of Riau to Surabaya.

Pangolins are among the world's most endangered species, and their scales are prized in countries like China and Vietnam, where they are used in traditional remedies even though they provide no scientifically proven medicinal benefit.